Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?

Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.’s share was trading at $40.29 as of April 20th. TVTX’s forward P/E was 54.35 , respectively according to Yahoo Finance.

robina-weermeijer–szKjHyPq28-unsplash

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. TVTX is approaching a critical commercial inflection point as adoption of its lead therapy Filspari accelerates, evidenced by a record 908 new patient start forms in Q4 2025, signaling that nephrologists are increasingly prioritizing long-term kidney preservation despite REMS-related friction.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Filspari’s dual endothelin and angiotensin receptor blockade differentiates it from traditional therapies and has been clinically validated by the Phase 3 PROTECT trial, which demonstrated a meaningful eGFR benefit versus irbesartan, positioning it as a foundational, non-immunosuppressive treatment in IgA nephropathy (IgAN).

The upcoming April 13, 2026 FDA decision for FSGS represents the key near-term catalyst, with approval potentially expanding the addressable market by ~50% and driving significant upside, while rejection would likely result in a limited pullback supported by growing IgAN cash flows.

Despite some methodological concerns in trials, particularly DUPLEX in FSGS, the long-term clinical relevance of Filspari’s kidney-preserving effects remains intact. Strategically, Travere is evolving into a focused nephrology player, supported by strong intellectual property protection and increasing M&A appeal amid consolidation in the renal space.

However, risks remain, including competition from Novartis’s atrasentan, potential regulatory setbacks, and the $316 million convertible debt due in 2029. Financially, the company is improving rapidly, with strong revenue growth, near-term profitability, and a clear path to free cash flow generation. Overall, Travere offers an asymmetric risk-reward profile, with limited downside and substantial upside driven by regulatory catalysts and commercial execution.

Previously, we covered a bullish thesis on AbbVie Inc. (ABBV) by Magnus Ofstad in May 2025, which highlighted the company’s strong Q1 performance, immunology-driven growth led by Skyrizi and Rinvoq, and pipeline strength with Elahere supporting long-term expansion. ABBV’s stock price has appreciated by approximately 2.64% since our coverage. BioEquity Watch shares a similar view but emphasizes on Travere’s regulatory-driven upside and Filspari-led commercial inflection.

Travere Therapeutics, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 47 hedge fund portfolios held TVTX at the end of the fourth quarter which was 50 in the previous quarter. While we acknowledge the risk and potential of TVTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TVTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

Disclosure: None.